CARMA FUND

Accelerate translation

The fund initiated by Ascenion and Innovectis invests in early-stage life-science technologies across the entire life-science and medical spectrum. The current volume is around EUR 60 million.

The objective of the CARMA Fund is to provide effective and efficient support for promising projects, free of bureaucratic hurdles and independent of the commercialization route. Company founders, as well as researchers who do not wish to found a start-up, can use CARMA funds to advance their projects towards application.

The unusually long investment timeframe of 15+ years is tailored to the requirements of biomedical research and development. It gives early-stage projects sufficient time to mature, and investors and the institutes involved the chance to participate in revenues.

The resulting income can be reinvested into research, in turn generating new translation projects.

Interested?

Find out more and contact the CARMA Fund Management directly here.